1. Clinical & Scientific Overview
Otic Clotrimazole + Lignocaine (TIP-MED-000442, Reference Code [12.30]-C172) is classified under
Ophthalmological & Otic (ENT) Preparations (Ch 12) as a Topical Otic Fluoroquinolone, Imidazole Antifungal, Corticosteroid, Local Anaesthetic & Cerumenolytic Preparations.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Co-indexed constituent under primary monograph [12.30] (Otic Ciprofloxacin, Clotrimazole & Cerumenolytic Ear Drops). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.30], p. 169): Antibiotic/Steroid Otic: Ciplox-D (Cipla — Ciprofloxacin 0.3% + Dexamethasone 0.1%), Allegra-O / Otek-AC; Antifungal Otic: Candibiotic Plus (Glenmark — Clotrimazole 1% + Beclomethasone + Lignocaine), Candid Ear Drops; Cerumenolytic: Soliwax (NuLife), Clearwax (Cipla), Waxolve — Strengths & Dosage Forms: Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).
Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).
3. Mechanism of Action & Pharmacodynamics
Ciprofloxacin inhibits bacterial DNA gyrase (Pseudomonas/Staph in otitis externa); Clotrimazole inhibits fungal ergosterol synthesis (otomycosis); Paradichlorobenzene + Turpentine emulsify impacted cerumen.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute diffuse otitis externa ('swimmer's ear' — Ciprofloxacin/Steroid drops), fungal otitis externa / otomycosis (Aspergillus/Candida — Clotrimazole drops), and softening/dissolution of impacted earwax prior to syringing (Cerumenolytic drops)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Otitis Externa / Otomycosis: Instil 3–4 drops into the affected ear canal TDS–QDS for 7–10 days. Impacted Cerumen: Instil 5–10 cerumenolytic drops into the ear canal BD–TDS for 3–4 days, plugging gently with a moistened cotton pledget (avoid dry cotton wool which wicks away the active drops!).
Administration & Meal Timing: Topical otic instillation Only — NEVER instil ear-only glycerine/cerumenolytic drops into the eyes! | 3 to 4 times daily; warm bottle in palms for 1–2 minutes before instillation.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [12.30].
Renal & Hepatic: No systemic dose adjustment required.
Renal & Hepatic: No systemic dose adjustment required.
Renal & Hepatic: No systemic dose adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- TYMPANIC MEMBRANE PERFORATION RULE (OTOTOXICITY): In known or suspected perforated eardrum or grommet tubes, STRICTLY AVOID Aminoglycoside ear drops (Gentamicin, Neomycin, Framycetin, Polymyxin B) and Cerumenolytics/Alcohol (cause irreversible cochlear/vestibular deafness!). Non-ototoxic Ciprofloxacin 0.3% otic drops are the only safe choice when perforation is present.
Key Clinical Precautions: Renal & Hepatic: No systemic dose adjustment required.
8. Adverse Effects Profile
- Transient stinging/burning on instillation, local pruritus, temporary muffled hearing (as cerumen swells upon absorbing cerumenolytic drops — warn patient in advance!).
- Cochlear and vestibular ototoxicity (if aminoglycoside/chloramphenicol/cerumenolytic drops enter middle ear through a perforated drum), secondary fungal overgrowth (prolonged antibiotic/steroid drops >10 days), contact dermatitis (Benzocaine/Neomycin).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Minimal systemic absorption; avoid concurrent use of two different otic solutions without a 30-minute interval
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.30].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Hold dropper bottle in warm hands for 2 minutes before use (cold ear drops cause severe vertigo/dizziness!); lie on side with affected ear up, pull pinna upward & backward (downward & backward in children <3 yr), instil drops, press tragus 4 times, and stay tilted for 5 minutes.
- Meal & Clock Timing Instruction: Topical otic instillation Only — NEVER instil ear-only glycerine/cerumenolytic drops into the eyes! (3 to 4 times daily; warm bottle in palms for 1–2 minutes before instillation.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H (Antibiotic/Steroid Otic) / OTC (Cerumenolytic) | NLEM 2022: Yes (Ciprofloxacin 0.3% Drops, Clotrimazole 1% Drops) | Compendia: NFI 7th Ed 2026 / NLEM 2022
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ciprofloxacin 0.3% w/v (+ Dexamethasone 0.1% w/v) Sterile Drops (5 mL, 10 mL). Clotrimazole 1% w/v + Beclomethasone Dipropionate 0.025% w/v + Lignocaine HCl 2% w/v Ear Drops (5 mL, 10 mL). Paradichlorobenzene 2% + Benzocaine 2.7% + Chlorbutol 5% + Turpentine Oil 15% Ear Drops (10 mL).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.21] Latanoprost & Travoprost Ophthalmic (PGF2-Alpha Glaucoma Drops) — Prostaglandin F2-alpha Analogue Ophthalmic Solution (Uveoscleral
- [12.22] Carboxymethylcellulose Sodium (0.5% / 1% Lubricant Eye Drops) — Cellulose Polymer Ocular Lubricant / Artificial Tears (Viscoelast
- [12.30] Otic Ciprofloxacin, Clotrimazole & Cerumenolytic Ear Drops — Topical Otic Fluoroquinolone, Imidazole Antifungal, Corticosteroi
- [12.5]-C150 Brimonidine Tartrate — Topical Ophthalmic Beta-Blockers (Timolol), Prostaglandin Analogu